LENZ
LENZ Therapeutics, Inc.
$7.55
+0.03
(+0.40%)
Mkt Cap
236.73M
Volume
558,114
52W Range
6.61-50.4
Sector
Healthcare
Beta
1.67
EPS (TTM)
-3.60
P/E Ratio
-5.61
Revenue (TTM)
20.99M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 19.09M | 0 | 0 | 15.00M | 0 | 0 | 0 |
| Net Income | (82.13M) | (49.77M) | (69.97M) | (10.81M) | (70.76M) | (68.37M) | (109,000) |
| EPS | -2.85 | -2.34 | -15.30 | -12.89 | -8.54 | -8.24 | -0.01 |
| Free Cash Flow | (70.00M) | (59.86M) | (60.41M) | (94.57M) | (58.59M) | (10.27M) | (19,000) |
| FCF / Share | -2.43 | -2.81 | -7.42 | -12.06 | -7.07 | -1.24 | -0.00 |
| Operating CF | (69.17M) | (59.39M) | (60.38M) | (87.98M) | (52.85M) | (8.72M) | (19,000) |
| Total Assets | 305.88M | 215.30M | 70.38M | 46.95M | 18.34M | 22.56M | 6,000 |
| Total Debt | 350,000 | 1.38M | 329,000 | 250,000 | 0 | 0 | 2.21M |
| Cash & Equiv | 25.18M | 20.16M | 35.14M | 44.44M | 18.31M | 19.82M | 6,000 |
| Book Value | 284.34M | 204.08M | (92.71M) | (24.17M) | (14.21M) | (9.80M) | (2.22M) |
| Return on Equity | -0.29 | -0.24 | N/A | N/A | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.90M | 1.59M | 12.50M | 5.00M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (41.49M) | (35.90M) | (16.70M) | (14.91M) | (14.62M) | (12.65M) | (10.21M) | (10.25M) | (16.65M) | (23.69M) | (18.88M) | (14.73M) |
| EPS | -1.32 | -1.16 | -0.59 | -0.53 | -0.53 | -0.46 | -0.38 | -0.40 | -3.53 | -2.77 | -2.75 | -6.82 |
| Free Cash Flow | (33.60M) | (33.06M) | (9.03M) | (11.75M) | (16.16M) | (9.23M) | (10.77M) | (15.93M) | (23.94M) | (20.97M) | (13.09M) | (4.89M) |
| FCF / Share | -1.07 | -1.06 | -0.32 | -0.42 | -0.59 | -0.34 | -0.40 | -0.62 | -5.07 | -2.53 | -1.60 | -0.60 |
| Operating CF | (33.58M) | (33.02M) | (8.59M) | (11.51M) | (16.05M) | (9.08M) | (10.58M) | (15.79M) | (23.94M) | (20.97M) | (13.09M) | (5.25M) |
| Total Assets | 272.54M | 305.88M | 210.70M | 217.33M | 201.25M | 215.30M | 224.01M | 202.64M | 217.32M | 70.38M | 92.17M | 287.04M |
| Total Debt | 237,000 | 350,000 | 461,000 | 1.05M | 1.18M | 1.38M | 1.58M | 1.70M | 589,000 | 329,000 | 360,000 | 53.54M |
| Cash & Equiv | 24.77M | 25.18M | 25.40M | 37.61M | 23.04M | 20.16M | 41.05M | 84.03M | 200.36M | 35.14M | 42.85M | 128.51M |
| Book Value | 246.49M | 284.34M | 193.93M | 206.37M | 192.01M | 204.08M | 215.28M | 192.92M | 198.17M | (92.71M) | (69.57M) | 224.15M |
| Return on Equity | -0.17 | -0.13 | -0.09 | -0.07 | -0.08 | -0.06 | -0.05 | -0.05 | -0.08 | N/A | N/A | -0.07 |
LENZ News
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More
LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript
LENZ Therapeutics Q1 Earnings Call Highlights
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
LENZ Therapeutics: Speculative But Strong Buy
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week
LENZ Therapeutics (NASDAQ:LENZ) versus Abeona Therapeutics (NASDAQ:ABEO) Critical Comparison